The R-Pharm group of companies, together with the British developer Oncimmune Holdings, have signed an exclusive agreement to introduce the EarlyCDT Lung product for early detection of lung cancer to the Russian and Eurasian Customs Union countries.
The development of Oncimmune is a specific blood test technology that facilitates the early detection of lung cancer among patients of major risk groups.
It helps to detect cancer cells with an accuracy of 92%, detecting autoantibodies in the blood, which are produced by the body at the very early stages of tumor development.
Currently, more than 70% of cases of lung cancer in Russia are in the third and fourth stages of the disease, which leads to poor prognosis for survival.
Early CDT Lung technology helps diagnose up to 4 years earlier than other methods – which will positively influence this trend.
Another important effect of the use of technology is the reduction of false positive diagnostics of lung cancer with CT.
“Russia has a huge potential for introducing screening techniques as a country with a high proportion of the population at risk. The Oncimmune Holdings and R-Farm partnership will help expand the geography of EarlyCDT Lung as an early stage lung cancer screening product, ”said Adam M. Hill, CEO of the British company.
As part of the partnership, R-Pharm will have the opportunity to expand the geography of technology commercial use in the countries of the Commonwealth of Independent States (CIS).